ORDITURA, Michele
 Distribuzione geografica
Continente #
EU - Europa 4.329
NA - Nord America 3.846
AS - Asia 795
AF - Africa 19
SA - Sud America 14
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.020
Nazione #
US - Stati Uniti d'America 3.767
IE - Irlanda 1.387
UA - Ucraina 627
IT - Italia 624
GB - Regno Unito 471
DE - Germania 390
FR - Francia 322
CN - Cina 281
SG - Singapore 272
FI - Finlandia 168
SE - Svezia 142
GR - Grecia 117
KR - Corea 93
TR - Turchia 89
CA - Canada 72
VN - Vietnam 38
PL - Polonia 30
BE - Belgio 16
SC - Seychelles 13
NL - Olanda 11
CZ - Repubblica Ceca 10
JP - Giappone 7
MX - Messico 7
EU - Europa 6
NZ - Nuova Zelanda 6
ES - Italia 5
AU - Australia 4
BR - Brasile 4
IR - Iran 4
CO - Colombia 3
EG - Egitto 3
HK - Hong Kong 3
PE - Perù 3
BD - Bangladesh 2
CH - Svizzera 2
CL - Cile 2
PK - Pakistan 2
A1 - Anonimo 1
AL - Albania 1
AR - Argentina 1
AT - Austria 1
IL - Israele 1
IN - India 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
TH - Thailandia 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 9.020
Città #
Dublin 1.377
Jacksonville 935
Chandler 645
Santa Clara 194
Princeton 190
Singapore 180
Medford 172
Caserta 138
Bremen 122
New York 120
Roxbury 120
Ann Arbor 107
Boardman 103
San Mateo 95
Naples 82
Wilmington 76
Seoul 71
Woodbridge 59
Elora 52
Nanjing 46
Des Moines 45
Beijing 44
Napoli 41
Dong Ket 36
Cambridge 34
Munich 32
Jinan 31
Kraków 29
Ashburn 25
Los Angeles 21
Mountain View 20
Helsinki 19
Houston 18
Brussels 15
Norwalk 15
Aiello Del Sabato 14
Nanchang 13
Shenyang 11
Auburn Hills 10
Brno 10
Ottawa 10
Changsha 9
Tianjin 9
Düsseldorf 8
Hangzhou 8
Milan 8
Redwood City 8
Lappeenranta 7
Ningbo 7
Taizhou 7
Lanzhou 6
Salerno 6
Shanghai 6
Zhengzhou 6
Guangzhou 5
Hebei 5
Jiaxing 5
Kunming 5
Taiyuan 5
Toronto 5
Amsterdam 4
Aversa 4
Battipaglia 4
Boydton 4
Changchun 4
Haikou 4
Marigliano 4
Rome 4
San Nicola la Strada 4
Scottsdale 4
Somma Vesuviana 4
Trieste 4
Arzignano 3
Benevento 3
Bogotá 3
Canicattì 3
Casoria 3
Catania 3
Cattolica 3
Ercolano 3
Frattamaggiore 3
Gunzenhausen 3
Hanover 3
Jesi 3
Lima 3
Maynooth 3
Mugnano Di Napoli 3
Padova 3
Parma 3
Pomezia 3
Walnut 3
Xiangfen 3
Andover 2
Antea 2
Athens 2
Avellino 2
Bagnoli Irpino 2
Barcelona 2
Bari 2
Brusciano 2
Totale 5.626
Nome #
ONCOLOGIA MEDICA 148
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 104
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 92
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 89
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 86
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 84
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 83
Amifostine: a selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review) 78
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 77
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 77
Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review. 75
Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis 74
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 74
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 74
Clinical management of advanced gastric cancer: Role of new molecular drugs. 73
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 72
TRASTUZUMAB RESISTANCE IN BREAST CANCER 72
Farmacogenomica e cancro colorettale 69
Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. 69
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 68
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 67
CD 26-positive/CD 326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence 67
Combined CD133/CD44 Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer. 67
Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome 66
Treatment of gastric cancer. 66
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 65
Different Biomarkers address different colorectal cancer stem cell populations: who's the killer? 65
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 65
Chemoradiotherapy as adjuvant treatment of gastric cancer 63
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival 63
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 62
Cardiotossicità da antracicline: attualità e prospettive 62
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 62
Naples Prognostic Score, Based on Nutritional and Inflammatory Status, is an Independent Predictor of Long-term Outcome in Patients Undergoing Surgery for Colorectal Cancer 62
Behavior of circulating CD4+CD25+FOXP3* regulatory T cells in colon cancer patients undergoing surgery 62
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 61
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 61
Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion 60
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 60
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 60
The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. 59
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 59
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 59
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 59
The over-the-scope-clip (OTSC) system is effective in the treatment of chronic esophago-jejunal anastomotic leakage 59
Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience 59
Indocyanine Green Fluorescence Imaging-Guided Surgery in Primary and Metastatic Liver Tumors 59
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations 59
Integrated therapy in localized gastric cancer: targeted and tailored approach. 58
Determination of molecular marker expression can predict clinical outcome in colon carcinomas 58
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 58
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 58
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 58
Ventricular repolarization time indexes following anthracycline treatment 57
Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients 57
Il trattamento delle neoplasie polmonari nell’anziano 57
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 56
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery 56
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 56
Il linfoma primitivo della parotide: una localizzazione infrequente 56
Adult Wilms' tumor: a case report 56
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 56
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 56
Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies 55
Serum interleukin-10 is an independent prognostic factor in advanced solid tumors 55
A true splenic cyst producing carbohydrate antigen 19-9 and cancer antigens 50 and 125, but not interleukin 10 55
Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis 55
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 55
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 55
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study 54
Carcinoma dell'esofago 54
Targeting EGFR in Pancreatic Cancer Treatment. 54
Metachronous Gastrointestinal Stromal Tumors (Gists) or relapse of the primary tumor ? A challenging case of multiple Gists in an elderly patient 54
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 54
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 53
Cetuximab in the treatment of colorectal cancer. 53
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery 52
Atypycal presentation of Merkel cell carcinoma positive to polyomavirus DNA detection: experience from a single center 52
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 52
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 52
Preoperative chemo-radiotherapy for carcinoma of the esophagus 51
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group 51
Novel investigational drugs for gastric cancer 51
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients 51
Propensity score-matched comparison between complete mesocolic excision and classic right hemicolectomy for colon cancer 51
Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions 51
Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes’ A and B colon cancer patients undergoing potentially curative surgery 50
The new European gold standard treatment for rectum cancer 50
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma 50
Adjuvant chemotherapy of gastric cancer: which regimen? 49
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy 49
Emergenze ematologiche nel paziente neoplastico 49
Pancreatic neuroendocrine tumors: Nosography, management and treatment 49
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 49
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: A phase II study 48
Inflammatory and nutritional status is a predictor of long-term outcome in patients undergoing surgery for gastric cancer. Validation of the Naples prognostic score. 48
Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers ? A prospective study. 47
Impact of total fundoplication on esophageal transit: analysis by combined multichannel intraluminal impedance and manometry. 47
MEK inhibitor as a single agent and in combination with everolimus or sorafenib in a panel of colorectal cancer cell lines: implication for multitargeted approach 47
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 47
Totale 6.128
Categoria #
all - tutte 42.284
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.284


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020700 0 0 0 0 156 28 210 81 91 61 49 24
2020/20211.387 128 17 153 85 257 16 196 141 13 165 146 70
2021/20221.171 104 3 17 19 412 7 19 39 42 55 114 340
2022/20232.682 321 45 37 206 305 207 15 159 1.290 11 45 41
2023/20241.005 85 33 48 85 351 127 9 21 10 18 65 153
2024/2025493 22 94 40 76 261 0 0 0 0 0 0 0
Totale 9.557